# Allergan to acquire University of Sydney spinoff Elastagen

Allergan plc agreed to acquire Elastagen Pty Ltd, a clinical-stage company developing medical device products based on recombinant tropoelastin, for an upfront payment of US$95 million plus contingent payments.

- Type: Acquisition
- Announced: 2018-02-09
- Value: $95.0M
- Status: announced
- Products: recombinant tropoelastin-based medical devices
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Allergan](https://endata.com/companies/22562.md) (acquirer)
- [Elastagen](https://endata.com/companies/29974.md) (target)

## Sources

- [sydney.edu.au](https://www.sydney.edu.au/news-opinion/news/2018/02/09/allergan-to-acquire-university-of-sydney-spinoff-elastagen.html), 2018-02-09: "Elastagen Pty Ltd, a clinical stage company developing medical device products based on recombinant tropoelastin, today announced that it has entered into a definitive agreement under which Allergan plc, a leading global biopharmaceutical company, has agreed to acquire Elastagen."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.